RTP Mobile Logo
Oncology Today with Dr Neil Love: Gastroesophageal Cancers (Audio Program)
Released July 2021

Featuring an interview with Dr Jaffer Ajani. (Audio Program)

CE Information and Faculty Disclosures

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastroesophageal cancers.


    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
    • Describe the published research data with the use of immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric, GEJ and esophageal cancers, and optimally integrate these strategies into nonresearch treatment algorithms.
    • Recall available data with and the FDA approval of trastuzumab deruxtecan for patients with previously treated HER2-overexpressing gastric/GEJ cancers, and discern the current and future clinical applicability of this treatment strategy.
    • Recognize common and rare side effects associated with approved and investigational agents utilized in the care of patients with gastroesophageal cancers, and use this information to develop appropriate and effective supportive management plans.
    • Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for patients with gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible individuals.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Jaffer A Ajani, MD
    Professor of Medicine
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Grail Inc, Merck, Roche Laboratories Inc, Taiho Oncology Inc, Turning Point Therapeutics Inc, Zymeworks; Contracted Research (to Institution): Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Delta-Fly Pharma, Gilead Sciences Inc, Leap Therapeutics Inc, Merck, ProLynx Inc, Roche Laboratories Inc, Taiho Oncology Inc, Zymeworks; Data and Safety Monitoring Board/Committee: BeiGene Ltd.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly and Taiho Oncology Inc.

    Release date: July 2021
    Expiration date: July 2022

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):